Home - Annexon Biosciences
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	



		
		
	





 



  

	
the
start
of classical
complement-driven
diseases

Unlocking the next generation of complement therapies

We are focused on stopping C1q, the initiating molecule of the classical complement pathway, at the start to treat devastating autoimmune, neurodegenerative, and ophthalmic diseases of the body, brain and eye.

Our science

We target C1q to block all damaging components of the immune system’s classical complement pathway.

Learn more

Our pipeline

Our next generation of early complement inhibitors targets diseases of the body, brain and eye.

Learn more

Our people

We are passionate about delivering transformative therapies for people suffering from devastating complement-driven diseases.

Join us